Novo Nordisk is facing political pressure over high U.S. prices for its weight-loss drugs, Ozempic and Wegovy, as the U.S. presidential election approaches. The company's CEO testified before Congress, attributing pricing issues to pharmacy benefit managers (PBMs). Despite potential price cuts, demand for these drugs remains strong, and Novo Nordisk's U.S. revenues are expected to remain stable. The political focus on drug pricing is bipartisan, and increased M&A activity in the pharmaceutical sector is anticipated post-election.